Clinical trials: Tace
Hepatocellular Carcinoma
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
Chemoembolization (TACE) is used in the majority of advanced hepatocellular carcinomas. Randomized clinical trials indicated that TACE improves overall survival in patients with good liver function (Child-pugh A or B).
- Trial name
- NCT00921531
- Testing
- Thalidomide, TACE
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy
A glycyrrhizin-containing product, Stronger Neo-Minophagen C TM (SNMC; Minophagen Pharmaceutical Co.Ltd.,Tokyo,Japan),is widely used in Japan for suppression of hepatitis activity and for prevention of disease progression in…
- Trial name
- NCT04015245
- Testing
- Stronger Neo-Minophagen C
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chimei Medical Center
Hepatocellular Carcinoma
Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion
The aim of this study is to compare the efficacy of transarterial chemoembolization with adriamycin to transarterial chemoembolization with adriamycin/transarterial chemoinfusion with cisplatin combination in advanced…
- Trial name
- NCT01857726
- Testing
- Doxorubicin, Cisplatin
- Where
- South Korea
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
The purpose of the study is to observe the effect of TACE/HAIC combined with lenvatinib and sintilimab as a neoadjuvant therapy before liver resection in preventing the recurrence in high-risk patients with hepatocellular…
- Trial name
- NCT05250843
- Testing
- TACE/HAIC, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Recurrent Hepatocellular Carcinoma, Lenvatinib
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage.
- Conditions
- Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy, Ablation
- Trial name
- NCT06609850
- Testing
- TACE, Ablation, Lenvatinb
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma
This multicenter prospective nonrandomized study is to evaluate the efficacy of TACE combined with sorafenib compared with TACE monotherapy in term of overall survival in intermediate-stage HCC.
- Trial name
- NCT02529761
- Testing
- Sorafenib, TACE
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Air Force Military Medical University, China
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT04592029
- Testing
- TACE combined with sintilimab and bevacizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC)
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC).
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
- Trial name
- FAD-HCC-001 (NCT07314372)
- Testing
- Camrelizumab Plus Apatinib, TACE Plus Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 86 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Liver Cancer
Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Patients with primary and secondary liver cancer may participate in this study. The purpose is to perform an analysis of the effects of doxorubicin and its metabolite doxorubicinol on the body (doxorubicin pharmacokinetics )…
- Trial name
- NCT02753881
- Testing
- whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Hepatocellular Carcinoma, Liver Neoplasms
Enhanced Radiofrequency Ablation for Recurrent HCC Post-TACE Using Twin Internally Cooled-Perfusion Electrodes
This single-center, prospective study evaluates the therapeutic outcomes of saline-augmented bipolar radiofrequency ablation (RFA) with twin internally cooled-perfusion (TICP) electrodes for treating recurrent hepatocellular…
- Trial name
- ERFA (NCT07192172)
- Testing
- Bipolar radiofrequency ablation using twin internally cooled perfusion electrodes
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma, Portal Vein Thrombosis
Neo-TACE-HAIC for PVTT-HCC
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. During the disease course, 20%-50% patients suffered portal vein tumor thrombus (PVTT), which is characterized with poor outcome and low response for…
- Trial name
- NeoconceptC (NCT04181931)
- Testing
- neo-TACE-HAIC+Surgery, Surgery alone
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Hepatocellular Cancer
Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
To determine the maximum tolerated radiation dose with concurrent sorafenib for unresectable hepatocellular carcinoma that has not responded to transarterial chemoembolization.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
- Trial name
- NCT01618253
- Testing
- Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Hepatocellular Carcinoma
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
- Trial name
- NCT06371157
- Testing
- AK104, Lenvatinib, TACE
- Where
- 4 sites in China
- Volunteers
- 469 people
- Sponsor
- Akeso
Carcinoma, Hepatocellular
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
This study will look at whether our drug (sorafenib) in combination with chemotherapy delivered directly into your tumor using beads (DC Bead) will slow the progression of the disease.
- Trial name
- NCT00855218
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 107 sites in United States, Australia and 11 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of Sorafenib combined with transarterial chemoembolization as adjuvant treatment for resectable advanced…
- Trial name
- SOURCE (NCT04143191)
- Testing
- Sorafenib, Transarterial chemoembolization
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Sun Yat-sen University
Adebrelimab (SHR-1316), Bevacizumab
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
his is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic…
- Conditions
- Adebrelimab (SHR-1316), Bevacizumab, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07543783
- Testing
- Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Liver Cancer
HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer
To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.
- Trial name
- NCT07587034
- Testing
- HTAC, HAC, TAC
- Volunteers
- 315 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced…
- Conditions
- Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
- Trial name
- NCT05984511
- Testing
- I-125 Seeds Brachytherapy in PVTT, Transcatheter arterial chemoembolization, Atezolizumab plus Bevacizumab
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma, Transarterial Chemoembolization
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
This study aims to evaluate the safety and effectiveness of a combined treatment for patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery.
- Trial name
- NCT07281664
- Testing
- Transarterial chemoembolization (TACE), bevacizumab and atezolizumab
- Volunteers
- 30 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma, Bilirubinemia
Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.
- Trial name
- NCT03259581
- Testing
- Transarterial chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Minnesota